SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-026765
Filing Date
2022-10-20
Accepted
2022-10-20 16:58:49
Documents
17
Period of Report
2022-10-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20221019.htm   iXBRL 8-K 49089
2 EX-1.1 exhibit11-8xkofferdetailsu.htm EX-1.1 235744
3 EX-5.1 exhibit51-8xkofferdetailsu.htm EX-5.1 14044
4 EX-99.1 exhibit991-8xkofferdetails.htm EX-99.1 10335
8 denali_txlogox02a.jpg GRAPHIC 604226
9 image_1a.jpg GRAPHIC 365942
  Complete submission text file 0001628280-22-026765.txt   1826842

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20221019.xsd EX-101.SCH 1932
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20221019_lab.xml EX-101.LAB 23832
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20221019_pre.xml EX-101.PRE 12528
11 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20221019_htm.xml XML 10926
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 221321628
SIC: 2836 Biological Products, (No Diagnostic Substances)